Irvine-based Allergan and MAP Pharmaceuticals said this morning that Allergan has agreed to acquire MAP Pharmaceuticals, in a deal worth approximately $958M. Allergan said it will pay $25.00 per share for publicly held MAP Pharmaceuticals. MAP Pharmaceuticals develops biopharmaceuticals, with its lead product being LEVADEX, an orally inhaled drug under trials for treating migraines in adults.